Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cold Agglutinin Disease Real World Evidence Registry

Trial Profile

Cold Agglutinin Disease Real World Evidence Registry

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 09 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sutimlimab (Primary)
  • Indications Autoimmune haemolytic anaemia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CADENCE
  • Sponsors Recordati Rare Diseases; Sanofi

Most Recent Events

  • 05 Jun 2023 Planned End Date changed from 26 May 2028 to 2 Nov 2028.
  • 05 Jun 2023 Planned primary completion date changed from 26 May 2028 to 2 Nov 2028.
  • 04 Apr 2023 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top